The table below shows EyePoint Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$80.55M
-$53.12M
-$31.17M
-$16.84M
-$20.16M
-$15.10M
Capital expenditure
$997.00K
$276.00K
$1.19M
$484.00K
$149.00K
$0.00
Investing cash flow
$59.05M
$39.52M
$20.81M
$32.09M
-$56.44M
$0.00
Dividends paid
-
-
-
-
EYPT operating cash flow (10-K history)
EyePoint Pharmaceuticals, Inc. reported operating cash flow of -$240.11M for fiscal year 2025. That is down 90.2% from -$126.23M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$16.32M (FY 2016) to -$240.11M. Figures come from the company's audited annual reports as filed with the SEC.